

## AMENDMENTS TO THE CLAIMS

The following represents a complete listing of the claims in this application indicating the present status of each, including any amendments sought to be entered at this time. Any claims that have been canceled or withdrawn have been canceled or withdrawn without prejudice or disclaimer of any subject matter therein. The applicants specifically reserve the right to pursue any and all such claims in continuing and/or divisional applications. In this paper, claims 1-10, 12, 16-18 and 24-33 have been canceled and claims 19-20 and 22-23 have been amended. New claims 34-51 have been added.

Listing of the claims:

1-18(canceled).

19(currently amended). A system as in claim ~~18~~ 49 wherein said anti-abuse layer contains a binding agent that prevents extraction of said abusable substance of interest using a solvent selected from the group consisting of water, ethanol or combinations thereof.

20(currently amended). A system as in claim ~~18~~ 49 wherein said anti-abuse substance includes activated carbon.

21(currently amended). A system as in claim 19 wherein said anti-abuse substance includes activated carbon.

22(currently amended). A system as in claim ~~16~~ 19 wherein said anti-abuse substance includes an amount of an irritant.

23 (currently amended). A system as in claim ~~18~~ 21 wherein said anti-abuse substance includes an antagonist.

24-33 (canceled).

34 (new). A disposal system for a skin-worn transdermal patch device containing residual amounts of an abusable substance after use thereof on a patient, said system comprising:

- (a) a container separate from and independent of said skin-worn patch device and having an opening therein for receiving a skin-worn patch device containing a residual amount of an abusable substance therein;
- (b) an amount of an anti-abuse substance including an amount of an active agent in said container for treating said abusable substance in said patch device on contact, said anti-abuse substance including material selected from the group consisting of binding and adsorption agents that prevent later independent extraction of said abusable substance of interest using a solvent selected from the group consisting of water, ethanol or combinations thereof, such that insertion of said skin-worn patch device properly oriented into said container will cause said abusable substance in said skin-worn patch device to contact said anti-abuse substance; and
- (c) closure device for closing said disposable container thereby capturing said skin-worn patch device.

35(new). A system as in claim 34 wherein said anti-abuse substance includes an amount of activated carbon.

36(new). A system as in claim 35 wherein said anti-abuse substance contains a major fraction of activated carbon.

37(new). A system as in claim 34 wherein said container is in the form of a flexible pouch.

38(new). A system as in claim 34 wherein said closure device includes an adhesive seal.

39(new). A system as in claim 37 wherein said closure device includes an adhesive seal.

40(new). A system as in claim 36 wherein said container is in the form of a flexible pouch.

41(new). A system as in claim 40 wherein said closure device includes an adhesive seal.

42(new). A system as in claim 34 wherein a portion of said anti-abuse substance contains an amount of an agent selected from antagonists, irritants and mixtures thereof.

43(new). A system as in claim 35 wherein a portion of said anti-abuse substance contains an amount of an agent selected from antagonists, irritants and mixtures thereof.

44(new). A device as in claim 34 wherein said abusable substance is an opioid and said anti-abuse substance is substantially activated carbon.

45(new). A system as in claim 44 wherein said opioid includes fentanyl.

46(new). A disposal system for a skin-worn transdermal patch device containing residual amounts of an opioid substance after use thereof on a patient, said system comprising:

- (a) a container separate from and independent of said skin-worn patch device and having an opening therein for receiving a skin-worn patch device containing a residual amount of an opioid analgesic substance therein;
- (b) an amount of an activated carbon anti-abuse substance in said container for treating said residual opioid substance in said patch device on contact, wherein insertion of said skin-worn patch device properly oriented into said container will cause said abusable substance in said skin-worn patch device to contact said anti-abuse substance; and
- (c) closure device for closing said disposable container thereby capturing said skin-worn patch device.

47(new). A system as in claim 46 wherein said opioid includes fentanyl.

48(new). A system as in claim 46 wherein a portion of said anti-abuse substance contains an amount of an agent selected from antagonists, irritants and mixtures thereof.

49(new). A skin-worn transdermal patch device for the administration of an abusable substance to a patient, comprising:

- (a) an anti-abuse layer in said patch device containing an amount of an active anti-abuse substance for treating said abusable substance on contact, said anti-abuse substance being selected from the group consisting of active binding agents for said abusable substance in said patch device, co-soluble antagonists, irritants and combinations thereof disposed in said patch device;
- (b) a source layer containing said abusable substance in said patch device;
- (c) a lightly adhering impermeable separator membrane situated between said anti-abuse layer and said source layer preventing contact therebetween during normal use of said patch when said patch device is adhered to the skin of a user; and
- (d) an extension device associated with said separator membrane provided with an aspect that adhesively adheres to the skin of a user in a manner that produces automatic withdrawal of said separator membrane from between said layer containing said anti-abuse substance and said source containing said abusable substance upon removal of said patch from the skin of said user thereby allowing the anti-abuse layer to contact the abusable substance source layer.

50(new). A device as in claim 49 wherein said abusable substance is an opioid and said anti-abuse substance contains a major fracture of activated carbon.

51(new). A system as in claim 49 wherein a portion of said anti-abuse substance contains an amount of an agent selected from antagonists, irritants and mixtures thereof.